ASC930 / ASC Therapeutics, City of Hope, Karolinska Institute, Stanford University - LARVOL DELTA

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: ASC Therapeutics | Trial completion date: Sep 2023 ➔ Apr 2026 | Trial primary completion date: Sep 2023 ➔ Jan 2026

Trial completion date • Trial primary completion date • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology

Essential Biomarkers for a Clinical Study of a Novel Allogeneic Cell Therapy for Acute Graft-versus-Host Disease (ISTH 2022) - P2 | "ASC Therapeutics has developed ASC930, an allogeneic cell therapy consisting of DSCs for the treatment of patients with Steroid Refractory aGVHD (SR-aGVHD) and concomitant biomarkers to profile therapeutic screening and monitoring... Preliminary clinical work using labeled DSCs showed that the cells travel to the lungs, then to the spleen and liver (Erkers 2015). These results are being assessed in vivo with the methodology described above, focusing on DSC pharmacokinetics and pharmacodynamics, as well as immune and therapeutic response. Conclusion(s): The introduction of selective biomarkers of cellular, immune, and disease response to DSCs can help select the right patient, the right treatment, and the right monitoring in the treatment of aGVHD."

Biomarker • Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Oncology • Transplantation • REG3A